Peregrine Capital Management LLC Trims Holdings in Kiniksa Pharmaceuticals International, plc $KNSA

Peregrine Capital Management LLC reduced its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 6.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 288,636 shares of the company’s stock after selling 20,554 shares during the quarter. Peregrine Capital Management LLC’s holdings in Kiniksa Pharmaceuticals International were worth $7,987,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Corebridge Financial Inc. lifted its stake in Kiniksa Pharmaceuticals International by 3.6% during the first quarter. Corebridge Financial Inc. now owns 15,979 shares of the company’s stock worth $355,000 after purchasing an additional 549 shares during the last quarter. GAMMA Investing LLC lifted its stake in Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock worth $27,000 after purchasing an additional 568 shares during the last quarter. Sound View Wealth Advisors Group LLC increased its position in Kiniksa Pharmaceuticals International by 4.0% in the first quarter. Sound View Wealth Advisors Group LLC now owns 14,657 shares of the company’s stock worth $326,000 after buying an additional 568 shares during the period. Martingale Asset Management L P lifted its stake in Kiniksa Pharmaceuticals International by 1.3% in the first quarter. Martingale Asset Management L P now owns 50,000 shares of the company’s stock valued at $1,111,000 after buying an additional 640 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Kiniksa Pharmaceuticals International by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock valued at $507,000 after buying an additional 1,002 shares during the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Stock Performance

KNSA opened at $40.60 on Tuesday. Kiniksa Pharmaceuticals International, plc has a one year low of $17.82 and a one year high of $40.89. The company has a market capitalization of $3.01 billion, a PE ratio of 1,015.25 and a beta of 0.16. The stock’s fifty day moving average is $36.56 and its 200-day moving average is $30.63.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The company had revenue of $156.80 million for the quarter, compared to analysts’ expectations of $145.21 million. On average, equities research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, CAO Michael R. Megna sold 50,490 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, October 20th. The stock was sold at an average price of $38.87, for a total value of $1,962,546.30. Following the transaction, the chief accounting officer directly owned 27,046 shares in the company, valued at $1,051,278.02. The trade was a 65.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Sanj K. Patel sold 121,248 shares of the business’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $38.90, for a total value of $4,716,547.20. Following the sale, the chief executive officer directly owned 111,794 shares in the company, valued at $4,348,786.60. This trade represents a 52.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 905,298 shares of company stock worth $32,343,574. 53.48% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Wedbush raised their target price on Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the company an “outperform” rating in a research note on Monday, October 13th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Wells Fargo & Company boosted their price objective on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research report on Thursday, September 25th. Finally, Jefferies Financial Group increased their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday, July 29th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $46.86.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.